VANCOUVER, Sept. 30 /CNW/ - Protox Therapeutics Inc. (TSX:PRX), a leader
in the development of receptor targeted fusion proteins, announced today that
it has appointed Dr. Jack Geltosky to its Board of Directors. Dr. Geltosky is
the Senior Vice President of Business Development at the Arizona Technology
Enterprise where he is responsible for developing business strategies,
licensing and partnering in the life sciences sector. He has been in the
pharmaceutical industry for more than 27 years and has extensive experience
with numerous and diverse deal structures in the licensing and partnering
arena.
